These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9425889)

  • 21. Cancer predisposition: where's the phosphate?
    Smith A; Ashworth A
    Curr Biol; 1998 Mar; 8(7):R241-3. PubMed ID: 9545192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor suppressor genes in lung cancer.
    Virmani AK; Gazdar AF
    Methods Mol Biol; 2003; 222():97-115. PubMed ID: 12710682
    [No Abstract]   [Full Text] [Related]  

  • 23. Pten is essential for embryonic development and tumour suppression.
    Di Cristofano A; Pesce B; Cordon-Cardo C; Pandolfi PP
    Nat Genet; 1998 Aug; 19(4):348-55. PubMed ID: 9697695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
    Maxwell GL; Risinger JI; Tong B; Shaw H; Barrett JC; Berchuck A; Futreal PA
    Gynecol Oncol; 1998 Jul; 70(1):13-6. PubMed ID: 9698466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression.
    Somerville RP; Shoshan Y; Eng C; Barnett G; Miller D; Cowell JK
    Oncogene; 1998 Oct; 17(13):1755-7. PubMed ID: 9796706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation analysis of the PTEN/MMAC1 gene in lung cancer.
    Forgacs E; Biesterveld EJ; Sekido Y; Fong K; Muneer S; Wistuba II; Milchgrub S; Brezinschek R; Virmani A; Gazdar AF; Minna JD
    Oncogene; 1998 Sep; 17(12):1557-65. PubMed ID: 9794233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No evidence of germline PTEN mutations in familial prostate cancer.
    Forrest MS; Edwards SM; Hamoudi RA; Dearnaley DP; Arden-Jones A; Dowe A; Murkin A; Kelly J; Teare MD; Easton DF; Knowles MA; Bishop DT; Eeles RA
    J Med Genet; 2000 Mar; 37(3):210-2. PubMed ID: 10777362
    [No Abstract]   [Full Text] [Related]  

  • 28. PTEN/MMAC1/TEP1 involvement in primary prostate cancers.
    Pesche S; Latil A; Muzeau F; Cussenot O; Fournier G; Longy M; Eng C; Lidereau R
    Oncogene; 1998 Jun; 16(22):2879-83. PubMed ID: 9671408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary breast cancer.
    Ellisen LW; Haber DA
    Annu Rev Med; 1998; 49():425-36. PubMed ID: 9509273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.
    Cheney IW; Johnson DE; Vaillancourt MT; Avanzini J; Morimoto A; Demers GW; Wills KN; Shabram PW; Bolen JB; Tavtigian SV; Bookstein R
    Cancer Res; 1998 Jun; 58(11):2331-4. PubMed ID: 9622068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN mutations in gliomas and glioneuronal tumors.
    Duerr EM; Rollbrocker B; Hayashi Y; Peters N; Meyer-Puttlitz B; Louis DN; Schramm J; Wiestler OD; Parsons R; Eng C; von Deimling A
    Oncogene; 1998 Apr; 16(17):2259-64. PubMed ID: 9619835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTEN: sometimes taking it off can be better than putting it on.
    Myers MP; Tonks NK
    Am J Hum Genet; 1997 Dec; 61(6):1234-8. PubMed ID: 9399917
    [No Abstract]   [Full Text] [Related]  

  • 33. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.
    Kim SK; Su LK; Oh Y; Kemp BL; Hong WK; Mao L
    Oncogene; 1998 Jan; 16(1):89-93. PubMed ID: 9467947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
    Guldberg P; thor Straten P; Birck A; Ahrenkiel V; Kirkin AF; Zeuthen J
    Cancer Res; 1997 Sep; 57(17):3660-3. PubMed ID: 9288767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer.
    Cooney KA; Tsou HC; Petty EM; Miesfeldt S; Ping XL; Gruener AC; Peacocke M
    Clin Cancer Res; 1999 Jun; 5(6):1387-91. PubMed ID: 10389923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers.
    Yokomizo A; Tindall DJ; Drabkin H; Gemmill R; Franklin W; Yang P; Sugio K; Smith DI; Liu W
    Oncogene; 1998 Jul; 17(4):475-9. PubMed ID: 9696041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN and myotubularins: families of phosphoinositide phosphatases.
    Taylor GS; Dixon JE
    Methods Enzymol; 2003; 366():43-56. PubMed ID: 14674238
    [No Abstract]   [Full Text] [Related]  

  • 39. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
    Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate.
    Dong JT; Sipe TW; Hyytinen ER; Li CL; Heise C; McClintock DE; Grant CD; Chung LW; Frierson HF
    Oncogene; 1998 Oct; 17(15):1979-82. PubMed ID: 9788441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.